Tashir Medica investment company and Russian pharmaceutical manufacturer Amedart have signed a memorandum on strategic cooperation in the field of pharmaceuticals and biotechnology, the company reports.
“Over the next 10 years, the companies intend to develop strategic cooperation in import substitution projects aimed at the joint development of vital medicines and their domestic production,” the report says.
The partnership between Tashir Medica and Amedart is intended for the development of a common strategy for creating innovations in the pharmaceutical and biotechnology market and conducting joint research.
The parties expressed hope that the cooperation would allow them to significantly develop pharmaceutical production to provide the population with high-quality, effective and safe medicines.
The interests of the parties include the implementation of the import substitution policy by domestic production of antiretroviral, antitumor, antidiabetic, prescription, and over-the-counter drugs for the hospital sector.
The companies intend to cooperate closely in a number of areas in the field of digitalization of healthcare. Relying on international experience, they will assist in the creation of a new digital ecosystem that promotes the acceleration of scientific, technological and socially-oriented development of the pharmaceutical industry.